3 Citations (Scopus)


Population-level survival has increased for a number of hematologic malignancies.1–3 Multiple myeloma, in particular, has seen improved survival both in clinical trials4–8 and on the population level.3,9–11 However, it is not known whether the changes in survival for myeloma have extended to other, less common plasma cell or plasmacytoid malignancies such as lymphoplasmacytic lymphoma (LPL, includes Waldenström’s macroglobulinemia (WM)), plasma cell leukemia (PCL), and solitary plasmacytoma (SP). Only a few population level studies of survival are available on LPL,12,13 PCL,14,15 and SP,16 with little information on changes in survival in the past decade.

Original languageEnglish
Issue number6
Pages (from-to)229-232
Number of pages4
Publication statusPublished - 01.01.2017

Research Areas and Centers

  • Research Area: Center for Population Medicine and Public Health (ZBV)


Dive into the research topics of 'Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21 st century'. Together they form a unique fingerprint.

Cite this